# Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

> **NCT02407561** · — · TERMINATED · sponsor: **Castle Biosciences Incorporated** · enrollment: 3 (actual)

## Conditions studied

- Rectal Adenocarcinoma
- Anal Adenocarcinoma
- Anal Squamous Cell Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02407561
- **Lead sponsor:** Castle Biosciences Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Futility - unable to secure sites and samples for participation
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407561, "Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02407561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*